Does Azilsartan Kamedoxomil Interact with Lithium?
CDI records a major classification for Azilsartan Kamedoxomil and Lithium. The stored summary is: Azilsartan reduces lithium renal clearance; chlorthalidone further reduces clearance. Combined effect increases serum lithium concentrations and risk of lithium toxicity. The mechanism involves reduced renal clearance of lithium by angiotensin ii receptor antagonist and diuretic. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Azilsartan Kamedoxomil Class
- Thiazide-like Diuretic
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Reduced renal clearance of lithium by angiotensin II receptor antagonist and diuretic
What To Tell Your Doctor or Pharmacist
If you are taking Azilsartan Kamedoxomil and your doctor is considering prescribing Lithium (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider